Iridex Corp (IRIX) Stock Price & Analysis
Iridex Corp (IRIX) rose 0.90% to USD 1.12 as of June 10, 2026 at 03:32 UTC, according to Nexqual real-time market data.
IRIX last closed at USD 1.11; the session ranged USD 1.1–1.16 on volume of 87,539 shares. Market capitalization is $19.50M, with a 52-week range of USD 0.87–1.65 (NCM). Source: Nexqual, June 10, 2026 at 03:32 UTC.
Key Statistics (as of June 10, 2026 at 03:32 UTC)
| Price | USD 1.12 |
|---|---|
| Change | ▲ 0.90% (up) |
| Previous Close | USD 1.11 |
| Open | USD 1.1 |
| Day Range | USD 1.1 – 1.16 |
| 52-Week Range | USD 0.87 – 1.65 |
| Volume | 87,539 shares |
| Market Cap | $19.50M |
| Exchange | NCM |
Technical Analysis (IRIX)
Nexqual's technical model rates IRIX "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 03:32 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.3 (neutral) |
| vs SMA50 | Above (USD 1.04) |
| MACD | 0.02 (positive) |
Analyst Ratings (IRIX)
Wall Street analysts rate IRIX "None" based on 1 analysts, with a mean price target of USD 2.75 (range USD 2.75–2.75), per Nexqual as of June 10, 2026 at 03:32 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 2.75 |
| High Target | USD 2.75 |
| Low Target | USD 2.75 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (IRIX)
| Next Earnings Date | 2026-08-18 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $13.59M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.03 vs est -0.07 ▲ beat |
| 2025-12-31 | USD 0 vs est -0.02 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
Financials & Fundamentals (IRIX)
| Total Revenue | $52.58M |
|---|---|
| Revenue Growth (YoY) | -0.80% |
| Gross Margin | +35.97% |
| Operating Margin | -2.75% |
| Profit Margin | -6.23% |
| ROE | -56.54% |
| Debt / Equity | 90.36 |
| Current Ratio | 1.92 |
| Total Cash | $4.59M |
| Total Debt | $4.28M |
| Free Cash Flow | $990,750 |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
Financial Health Score (IRIX)
Nexqual rates Iridex Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:32 UTC.
| Growth | Weak — Revenue -1% YoY (latest Q), declining |
|---|---|
| Profitability | Weak — Gross margin 36%, operating -3% |
| Balance Sheet | Mixed — $5M cash vs $4M debt, net cash position |
| Cash Flow | Mixed — FCF $991K, slim 1.9% margin |
| Efficiency | Critical — ROE -57%, ROA -5.4% |
Ownership (IRIX)
| Insider Ownership | +28.86% |
|---|---|
| Institutional Ownership | +18.04% |
| Shares Outstanding | 17.41M |
| Float | 11.39M |
| Short % of Float | +0.25% |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
Leadership (IRIX)
Iridex Corp is led by Patrick Mercer (age 53), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:32 UTC.
| CEO, President & Director | Patrick Mercer (age 53) |
|---|---|
| Executive Chairman | Scott A. Shuda (age 60) |
| Chief Financial Officer | Romeo R. Dizon (age 67) |
Major Backers & Investors (IRIX)
Notable institutional backers of Iridex Corp include Paragon Associates & Paragon Associates Ii Joint Venture, Renaissance Technologies, Weber Capital Management LLC /ADV, according to Nexqual as of June 10, 2026 at 03:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Paragon Associates & Paragon Associates Ii Joint Venture | 5.74% |
| Renaissance Technologies | 2.28% |
| Weber Capital Management LLC /ADV | 1.49% |
| Fidelity | 0.78% |
| Citadel | 0.35% |
| United Capital Financial Advisors, LLC | 0.33% |
| Perkins Capital Management, Inc. | 0.32% |
| Thompson Davis & Company Inc. | 0.27% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.27% |
| Geode Capital | 0.92% |
Source: Nexqual, June 10, 2026 at 03:32 UTC.
From Iridex Corp's Latest SEC 10-K Filing (filed 2026-04-02)
Key Strengths & Strategy (as disclosed to the SEC)
- IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology.
- It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
- The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders.
- In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ICCC | ImmuCell Corporation | USD 9.77 | ▲ 1.66% |
| FOCL | EDAP TMS S.A. | USD 4.52 | ▼ 0.88% |
| CPIX | Cumberland Pharmaceuticals Inc. | USD 5.72 | ▼ 1.38% |
| OFIX | Orthofix Medical Inc. | USD 9.87 | ▼ 4.08% |
| INFU | InfuSystems Holdings, Inc. | USD 9.01 | ▼ 2.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:32 UTC. This page is informational and not investment advice.